Added value of this study
In the present study, we observed that the administration of an HIV-1 therapeutic vaccine together with the latency reversing agent RMD has an impact on the plasma proteomic profiles, including inflammatory and neurological markers. In particular, we identify the CD33 protein, also known as sialic acid binding immunoglobulin-like lectin 3 (Siglec-3), as a soluble plasma marker that can discriminate MAP-C from MAP-NC already at baseline time points before RMD and vaccine administration. Validation analyses in an unrelated cohort of chronically HIV-1+ individuals and 